We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+37.22%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$296M
AUM Growth
-$29.1M
Cap. Flow
-$68.9M
Cap. Flow %
-23.29%
Top 10 Hldgs %
37.63%
Holding
99
New
29
Increased
28
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$7.19M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.21M
3
VRAY
ViewRay, Inc.
VRAY
+$5.34M
4
PLRX icon
Pliant Therapeutics
PLRX
+$4.01M
5
NKTX icon
Nkarta
NKTX
+$3.6M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$9.29M
2
APLS
Apellis Pharmaceuticals
APLS
+$5.87M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$4.91M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.34M
5
BIIB icon
Biogen
BIIB
+$4.25M

Sector Composition

Rank Sector Weight
1 Healthcare 76.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TERN
76
DELISTED
Terns Pharmaceuticals
TERN
$85K 0.03%
+14,473
New +$53.8K
PYPD icon
77
PUT
PolyPid
PYPD
$82.3M
$59K 0.02%
+1,667
New +$206K
RCOR.WS
78
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$8K ﹤0.01%
104,828
– –
MSACW
79
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$1K ﹤0.01%
49,990
– –
ALGS icon
80
Aligos Therapeutics
ALGS
$26.2M
– –
-2,336
Closed -$71K
ALNY icon
81
CALL
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-40,000
Closed -$5.83M
APLS
82
DELISTED
Apellis Pharmaceuticals
APLS
– –
-129,795
Closed -$5.87M
BIIB icon
83
Biogen
BIIB
$30B
– –
-20,825
Closed -$4.25M
CGEN icon
84
Compugen
CGEN
$222M
– –
-104,150
Closed -$193K
CLDX icon
85
PUT
Celldex Therapeutics
CLDX
$2.99B
– –
-36,000
Closed -$971K
DAWN
86
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-105,476
Closed -$1.89M
MREO
87
Mereo BioPharma
MREO
$54.7M
– –
-156,195
Closed -$175K
PYPD icon
88
PolyPid
PYPD
$82.3M
– –
-5,386
Closed -$666K
QQQ icon
89
PUT
Invesco QQQ Trust
QQQ
$453B
– –
-162,500
Closed -$45.5M
SNDX icon
90
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-107,852
Closed -$2.08M
SPRY icon
91
ARS Pharmaceuticals
SPRY
$509M
– –
-209,108
Closed -$887K
XBI icon
92
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-208,300
Closed -$15.5M
ZYME icon
93
Zymeworks
ZYME
$1.61B
– –
-208,330
Closed -$1.1M
HGEN
94
PUT
DELISTED
HUMANIGEN, INC.
HGEN
– –
-781,100
Closed -$1.38M
OTIC
95
DELISTED
Otonomy, Inc.
OTIC
– –
-1,041,273
Closed -$2.17M
CCXI
96
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-26,036
Closed -$645K
FMTX
97
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-94,386
Closed -$650K
CFRX
98
PUT
DELISTED
ContraFect Corporation
CFRX
– –
-19,536
Closed -$4.8M
BHVN
99
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-26,374
Closed -$3.84M
1 2 3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Silverarc Capital Management held 99 positions worth $296M, down 9% from $325M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Silverarc Capital Management withdrew a net $68.9M in Q3 2022, closing 20 positions and reducing 20 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $5.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 65% a quarter earlier.

Against the trend, Silverarc Capital Management opened a new position in Alnylam Pharmaceuticals worth $6.51M.

  • Silverarc Capital Management's largest Q3 2022 buy was Alnylam Pharmaceuticals: 32,545 shares worth $6.51M.
  • Silverarc Capital Management added most to Poseida Therapeutics, Inc. Common Stock in Q3 2022, an estimated $7.19M increase.
  • Silverarc Capital Management's biggest Q3 2022 reduction was Intra-Cellular Therapies Inc., cutting an estimated $9.29M.
  • Silverarc Capital Management fully exited Apellis Pharmaceuticals in Q3 2022, selling an estimated $5.87M.
  • Silverarc Capital Management's ten largest holdings make up 38% of its $296M portfolio in Q3 2022.
  • Silverarc Capital Management opened 29 new positions and closed 20 in Q3 2022.
  • Silverarc Capital Management's portfolio value fell 9% quarter-over-quarter to $296M.

Based on Silverarc Capital Management's 13F filing for Q3 2022, filed 28 Oct 2022.